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Objectives: to predict the costs and effects on life expectancy of an AAA screening programme.
Methods: a Markov model was designed to compare the effects of a single screening for a cohort of men 60±65 years with
the current no screening strategy. The following health states were distinguished: no AAA, unknown small AAA, follow-up
small AAA, unknown large AAA, repaired AAA, rejected large AAA and death. Transition rates between the health states
were simulated using cycle times of one year. Transition probabilities were derived from literature and a previous feasibility
study. Incremental costs per life year saved were calculated. Sensitivity analyses and discounting for future effects were
performed.
Results: the expected individual AAA costs for non-screening and AAA screening were d196 and d530 respectively. A
difference of 3.5 months life expectancy was found in favour of screening leading to d1176/life-year gained. Costs increased
as compliance fell. With a discount rate of 4% the costs are d2021/life-year gained.
Conclusions: one-time ultrasonographic screening for AAA in men aged 60±65 years appears to be cost-effective.
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Introduction
The incidence of ruptured abdominal aortic aneurysm
(AAA) appears to be increasing in developed coun-
tries. Ruptured AAA is believed to be responsible for
2% of all male deaths over the age of 60 years, and
rupture is associated with a community mortality of
80±90%.1±5 In screening studies the prevalence of
AAA in men over 60 years is estimated to be 4.3±
8.3% although the definition of what is considered to
be an AAA differs considerably between screens.6±9
Several graphs have demonstrated that community
screening for AAA reduces mortality from
rupture.10±13
In the Netherlands study where all eligible
male patients between 60±80 years were selected for
screening by their family doctor.9 The attendance rate
was 83%. The prevalence of an AAA (defined as an
aortic diameter430 mm) was 8.1% (95% confidence
interval 7.0±9.2%). Twenty percent of these patients
had an AAA 450 mm and were referred for surgical
repair.
The objective of our study is to establish the impact
of a mass-screening program for AAA on life expect-
ancy and cost. To achieve this objective, one can con-
duct a controlled clinical trial. A prospective study
could produce data about added lifetime and eco-
nomic consequences, but would be extensive, time
consuming and costly. Only recently controlled clinic-
al trials were started and it will take a considerable
period of time before they can answer these long term
matters. Another method to calculate costs and effects
of screening on AAA over a long time frame is a
modeling study. The model can be based on data
from previous studies. The aim of the present study
was to develop a Markov model to calculate the effects
of a screening strategy for men aged 60±65 years in the
Netherlands.9,14
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Material and Methods
The Markov model
The Markov model is represented in Figure 1. Seven
possible health outcomes or Markov states were
defined.
Health states and transitions
The following health states were distinguished: no
AAA, unknown small AAA, follow-up small AAA,
unknown large AAA, repaired AAA, rejected large
AAA and death (see Fig. 1). Health states are mutually
exclusive and collectively exhaustive, meaning that at
any given time each person in the population being
modeled must be in one of the possible health states,
and each person cannot be in more than one state at
the same time.
Health state `` no AAA'' includes men with an aortic
diameter 530 mm, who have a life expectancy as is
registered by the Dutch Central Bureau for Statistics.
Compared with the health state `` unknown small
AAA'', diameter between 30±50 mm, the state
`` unknown large AAA'', diameter 50 mm or above,
represents a significantly higher risk of rupture.
A distinction between small AAA (30±50 mm diam-
eter) versus a large AAA (450 mm diameter) is made
because of differences in natural history and subse-
quently different strategy in asymptomatic AAA.
When small AAA is detected follow-up is initiated
until the chance of rupture justifies repair. This health
state is called `` follow-up small AAA''. Subjects known
to have large AAA are considered candidates for pre-
ventive repair. Elective treatment will be denied when
the life extension due to the intervention is judged to
be insignificant compared with the life expectancy.
This judgment can be made by the patient, the medical
staff or both. This health state is labeled as `` rejected
large AAA''.
Repair of AAA is undertaken to exclude the life
threatening condition of a rupture. At this moment
the long-term durability, mortality and costs of the
open repair of AAA are well known. In this model,
intervention is assumed to be open repair. The condi-
tion after this operation is defined as a separate health
state `` repaired AAA'', because in this state one will
not undergo a transition to AAA developmen again.
Paradoxical, `` death'' is defined as a separate health
state. Death is the state wherein everybody ends after
a certain time. Death is called the absorbing state.
At the start of the simulation, the subjects are
divided over different health states according to
Fig. 1. Health states, definitions and transition possibilities in the Markov model.
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known prevalence, except `` death''. The assumption is
made that at the start no AAA is detected or operated
on. The cycle time used in this model is a fixed inter-
val of one year. Every year an individual can move to
another health state with a certain transition probabil-
ity. The so-called transitions can be caused by different
events. The chance of a transition is defined by the risk
of such an event to happen in this fixed time period.
The members of the cohort were followed during their
lifetime until 99% of simulated patients reached the
death state. The difference in life expectancy and costs
were calculated for both strategies.
Transition probabilities
The transition probabilities are different according to
the health state of a virtual person. The chances of
transition from one state to another are calculated
based on demographic data from the Dutch Central
Bureau for Statistics, data collected during a feasibility
study in The Netherlands and published data.9 A
search of the Medline database was done for
reports on Abdominal Aortic Aneurysm since 1966.
The electronic database search was supplemented by
manual search of bibliographic reference lists of these
articles. In Table 1 the transition probabilities and the
chance for each cycle time are displayed. The prob-
abilities of some transitions are different for the two
studied strategies.
Costs
Costs are displayed in Euro (d) and based on the year
1997. Cost calculations were based on the feasibility
study performed. The design of that study is
described elsewhere.9 Fixed costs are incurred regard-
less of screening attendance as opposed to variable
costs that are patient related. (Tables 2 and 3). Treat-
ment costs are based on in hospital costs.
Sensitivity analysis
This Markov model is based on a broad set of deter-
minants. As the figures are based on published results
Table 1. Transition probabilities of the health states in the Markov model.
Parameters Transition
probability
(proportion/yr)
Health change Source
l1 2 10ÿ3 Dilatation aorta over 29 mm 9,15,16
l2 2 10ÿ1 Small AAA growth to 50 mm or more 11,17±25
l3.1 3 10ÿ4 Small AAA detection current policy 12,26,27
l3.2 97 10ÿ1 Small AAA detection screening program 9,12,27
l3.3 12 10ÿ5 Small AAA detection after screening program 9,12,26,27
l4.1 83 10ÿ2 Small AAA surgery due to symptoms 27
l4.2 38 10ÿ3 Small AAA surgery due to rupture 1,3,28±30
l5.1 26 10ÿ4 Large AAA detected but unfit or refusing repair current policy 9,27
l5.2 62 10ÿ1 Large AAA detected but unfit or refusing repair screening
program
9,27
l5.3 77 10ÿ6 Large AAA detected but unfit or refusing repair after screening
program
9,27
l6.1 14 10ÿ1 Large AAA detected and surgical repair current policy 9,12,27
l6.2 35 10ÿ1 Large AAA detected and surgical repair screening program 9,12,27
l6.3 43 10ÿ6 Large AAA detected and surgical repair after screening program 9,12,27
l6.4 36 10ÿ2 Large AAA ruptured and emergency repair 1,11,29±33
l7 17 10ÿ2 Small AAA during follow-up growth to large AAA but unfit or
refusing repair
9,11,17±25,27,34
l8.1 83 10ÿ2 Small AAA during follow-up surgical repair due to symptoms or
growth41 cm/year
27
l8.2 38 10ÿ3 Small AAA during follow-up acute repair due to rupture 1,3,28±30
l8.3 72 10ÿ2 Small AAA during follow-up growth to large AAA and surgical
repair
9,11,12,17±25,27
l9 36 10ÿ2 Large AAA unfit or refusing elective repair but acute repair due
to rupture
1,11,29±33
m1 75 10ÿ1 Mortality of ruptured AAA 1,3,28±30
m2 50 10ÿ1 Mortality of emergency repair of ruptured AAA 1,3,28±30,35±37
m3 68 10ÿ2 Mortality of elective surgery for AAA 1,35
mx Age specific Registered life expectancy for Dutch inhabitants Dutch Central
Bureau for
Statistics
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from particular numbers of patients, the rates and
probabilities used in the model have a certain accur-
acy. Some ranges of rates and probabilities are varied
in a sensitivity analysis. Sensitivity analysis is a wide-
ly accepted method to explore the uncertainty of
model results by varying its input parameters.38 The
sensitivity of the model is explored for different
attendance rates in order to display the variation of
outcomes. Both the influence on life expectancy and
the extra costs are calculated for attendance rates ran-
ging from 90% to a worst-case scenario of 10%.
There is a discrepancy between expenses for a pre-
ventive strategy towards AAA, which are merely
made in advance, and effect on life expectancy,
which in general is established years later.39 In general
it is accepted that we place greater value on an inter-
vention that offers immediate rather than delayed
health gains. Health economics introduced a method
of discounting in order to compensate for this effect.
The cost-effectiveness was calculated using discount
rate of 0, 2 and 4%. The current discount rate accord-
ing to Dutch guidelines is 4%.40
Results
Effect of screening on life expectancy
Implementation of a mass-screening program for
AAA instead of the current policy of detection by
chance increased the life expectancy according to the
Markov model. The life expectancy for men 60±65
years without screening was estimated to be 16.99
years beyond their current age. Simulation of the
same cohort in the model was based on the results
with a single ultrasound screening for AAA with
attendance of 83%. The model calculated an increased
life expectancy of all individuals of this group of 17.27
years.9,41 This is a prolongation of live for every man
in the cohort of 0.28 year, 3.5 months or 104 days.
Sensitivity analysis showed that life extensions differ
depending on attendance rates, ranging from 112 days
at an attendance rate of 90% to 12 days at a rate of 10%
(Table 4).
Cost of screening
When no screening for AAA is performed, the cost of
detection and prevention by chance and the treatment
attempts of ruptured AAA were estimated to be d196
per individual. The cost of mass screening for AAA
were calculated to be d530 for each individual in the
cohort. Sensitivity analysis showed that the cost per
individual ranges from d415 at an attendance rate of
10% to d555 at an attendance rate of 90%.
Cost-effectiveness of screening for AAA
Results from the Markov model using data from the
feasibility study indicate that a life extension of
104 days due to mass screening for AAA costs d334.
This means that living one extra day costs d3.22 and
one year extra costs d1176. Sensitivity analysis
resulted in d6446 per year saved at a 10% attendance
rate decreasing to d1164 per year extension when 90%
takes their chance of AAA detection (Table 4).
Table 4. Sensitivity analysis for different attendance rates at mass
screening and AAA related costs, life expectancy and costs/year
saved compared with current policy of detection by chance (costs
in 1997).
Attendance rate 90% 70% 50% 30% 10% Current
situation
Life-expectancy
in years
17.30 17.23 17.16 17.09 17.02 16.99
Increase life-
expectancy
days
112 88 62 38 12 0
Costs for AAA
treatment in d
per individual
555 485 420 369 415 196
Extra costs for
screening in d
per individual
359 289 224 173 219 0
Costs per life
year saved in d
1164 1204 1311 1683 6446 0
Table 2. Fixed costs in c/year for ultrasound screening
regardless attendance rate for capacity of 40 000 invita-
tions/year (costs in 1997).
Costs d/year
Ultrasound scanner 9100
Room rental 11 500
Administration 13 500
Manpower 29 500
Travel expenses 13 500
Telecommunication 20 000
Total expenses 97 700
Table 3. Variable costs for each patient in c (costs in
1997).
Costs d
Administration of each examination 15
Inform patient about AAA detected 65
Follow-up program 90/year
Elective surgical repair 10 000
Acute operation ruptured AAA 14 000
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The cost per year of extended life can be converted
to present day cost by discounting the immediate and
ongoing costs for future effects. The cost per year
extended life at a discount rate of 2 or 4% increase to
d1559 or d2021 respectively. Reduction for present-
day expenditure and outcome in the future for diverse
attendance rates was calculated for discount rates of 2
and 4% (Table 5 and Fig. 2).
Discussion
As the Markov model used in this study to cal-
culate the costs and effects of AAA screening is a
simplification. Results are likely to be less precise
than those from a randomised controlled trial.
Screening led to an increase in life expectancy of 3.5
months averaged across the whole cohort, which
translates in to a 3.5 year survival advantage for the
8% of the patients who had an AAA.
While an increase in life expectancy of 104 days (or
3.5 months) seem as impressive, it has to be remem-
bered. The reason is that these 3.5 months are added to
the lives of all the men studied which greatly dilutes
the effect of screening. In reality, however, only an 8%
prevalence exists of AAA meaning that only a minor
part of the cohort will benefit from a secondary
prevention program. When we apply the beneficial
consequences to a subpopulation including 8% of the
cohort with AAA, then this fraction of the studied
group with AAA will live roughly 3.5 years longer,
which, indeed, is about 12 times more than when the
benefit was spread over the whole group. Not only the
effect of screening is concentrated on the subpopula-
tion with AAA but also the majority of costs and
efforts are intended for this group at risk.
The number of men attending for screening, too
little influence on the cost per life-year saved. Even
when discounting for immediate and ongoing costs
for future effects at 4% the amount expended is
between d2000 and d2500 per life-year gained for
attendance rates of 40% or more.
Fig. 2. Costs per life year gained for different attendance rates. Discount rate for immediate costs for later effect.
Table 5. Amount in c per year extension for different attendance
rates and after correction by discounting for present-day cost and
outcome in the future. (Costs in 1997)
Attendance rate Discount rate
% 0% 2% 4%
90 1164 1546 2005
80 1181 1569 2038
70 1204 1604 2087
60 1242 1656 2160
50 1311 1739 2255
40 1431 1919 2472
30 1683 2269 2938
20 2407 3276 4263
10 6446 8731 11 416
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In our Markov model for men 60±65 years of age the
chances of transition (e.g., mortality and costs of treat-
ment) were based on published data. These data for
AAA treatment, however, concern patients who
generally are older than the study group. Age is an
independent risk factor for mortality.36,42,43 Given the
simulated effect of screening for AAA by our
Markov model, the outcome of secondary prevention
of AAA in practice can be expected to be even
more favorable, both in terms of survival and cost.44
Ironically, this argument also is supported by
opponents of mass screening, who raise the issue of
volunteer bias. Volunteer bias may be introduced
because those who accept the invitation for screening
may have a positive health attitude causing a better
prognosis. While this volunteer bias highlights a
potential discrepancy in prognosis between atten-
dants and non-attendants, it will have little impact
when compliance with mass screening for AAA is as
good as reported in the majority of studies.6±10
However, there is lack of data to estimate this favour-
able effect.
In our Markov model we assumed open repair of
AAA as the accepted method of intervention to pre-
vent rupture. The durability of the open surgical pro-
cedure has been established over the last 50 years. In
the short term, this procedure involves a substantial
mortality. Although implantation of a vascular pro-
thesis for AAA repair can cause difficulties in the
long run, complications occur infrequently. One retro-
spective study addressed this matter, describing 36
years of observation from a single institution with
eight graft related deaths (2.6%) out of 304 repairs.45
Therefore, the assumption was made in the design of
the model that after successful elective or emergency
aortic surgery, the AAA has vanished completely
and the simulated patient comes in the repaired
AAA state.
Although endovascular AAA management has
been implemented widely all over the world during
the last decade, the value of this experimental
approach has yet to be assessed. The costs of AAA
mass screening of about d2500 per life-year gained
compares favorably with many other expenses. It is
generally accepted is to spend d50 000 per year for life
extension by heamodialysis. Breast cancer screening
cost between d20 000 and d50 000 for each life year
gained, depending on the screening method and age
group. Preventive health interventions are considered
cost-effective when costs per life year saved are less
than d50 000.46
In conclusion, secondary prevention by mass
screening for AAA appears worthwhile. The question
shifts from `` Do we need to initiate mass screening for
AAA?'' to `` How should we introduce a mass screen-
ing program?''
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